Gallen Consensus (2009) states that the Ki-67 labeling index is a useful parameter with which to select patients with hormone receptor-positive breast cancers who may benefit from chemotherapy as well as endocrine therapy. The gene discussed is MKI67; the disease is breast carcinoma.